Enovis Corporation Reports 8.2% Net Sales Increase to $558.8 Million in Q1 2025

Enovis Corporation reported a net sales increase of 8.2% for the first quarter of 2025, reaching $558.8 million compared to $516.3 million in the same period last year. The growth was primarily driven by strong performance in the Reconstructive segment, which saw sales rise by 11.3% to $286.3 million, while the Prevention & Recovery segment increased by 5.2% to $272.6 million. The company also noted a gross profit of $332.2 million, up from $297.9 million, resulting in a gross profit margin of 59.4%, an increase from 57.7% in the prior year.

Despite the revenue growth, Enovis reported a net loss of $55.6 million for the quarter, an improvement from a loss of $71.8 million in the same period last year. The loss per share from continuing operations was $(0.98), compared to $(1.32) in the previous year. The company attributed the reduced loss to increased gross profit and lower other expenses, including a significant decrease in fair value losses on contingent acquisition shares and interest expenses.

Strategically, Enovis completed five bolt-on acquisitions in the first quarter of 2025 for a total consideration of $30 million, enhancing its product offerings in both the Prevention & Recovery and Reconstructive segments. The company also finalized the acquisition of LimaCorporate S.p.A. in January 2024, which has been integrated into its operations. The acquisitions are expected to contribute positively to future revenue growth and market share expansion.

Operationally, Enovis reported an increase in adjusted EBITDA to $99.2 million, up from $83.2 million, reflecting improved operational efficiency. The company’s total assets increased to $4.88 billion as of April 4, 2025, compared to $4.72 billion at the end of 2024. The company’s employee headcount also grew, reflecting its expansion efforts. However, cash and cash equivalents decreased to $38.5 million from $48.2 million, primarily due to cash used in investing activities related to acquisitions.

Looking ahead, Enovis remains focused on leveraging its acquisitions to drive growth and improve patient outcomes. The company anticipates continued revenue growth, although it acknowledges potential challenges from foreign currency fluctuations and market conditions. Enovis is committed to maintaining its operational efficiency and enhancing its product offerings to capture a larger share of the orthopedic solutions market.